Lobbying client
Quva Pharma, Inc.
Lobbies Congress through the outside firms below, which report what it paid them.
Reported spend, this Congress
$340K
Outside firms hired
1
Bills named in its reports
1
Issue areas
1
Spending by quarter, 2026
$50K
Q1 2026
$50K
Q2 2026
$50K
Q3 2026
—
Q4 2026
Earlier this Congress: Q1 2025 $40K · Q2 2025 $50K · Q3 2025 $50K · Q4 2025 $50K
Issues it lobbied on
1Pharmacy 5
Bills named in its reports
1| Bill | Status | Reports | Latest |
|---|---|---|---|
| S.3794Safeguarding Americans from Fraudulent and Experimental Drugs Act of 2026 or the SAFE Drugs Act of 2026 | Introduced | 2 | Q3 2026 |
Who lobbied for it
1| Registrant | Reported | Latest |
|---|---|---|
| VAN Scoyoc AssociatesOutside firm | $340K | Q3 2026 |
Reports
7From Lobbying Disclosure Act reports filed with Congress. Each quarter counts once per organization: its own in-house report when it filed one, which already includes what it paid outside firms, otherwise the sum of its firms' reports. Amended reports replace the original. Firms report nothing under $5,000 a quarter. Reports name the bills lobbied on but not how the money was split between them, so bills show organizations, not dollars.